DrugPatentWatch Database Preview
Pharmacyclics Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
PHARMACYCLICS INC has two approved drugs.
There are thirty-nine US patents protecting PHARMACYCLICS INC drugs.
There are two hundred and sixty-two patent family members on PHARMACYCLICS INC drugs in forty-one countries and thirty-two supplementary protection certificates in fourteen countries.
Summary for Pharmacyclics Inc
International Patents: | 262 |
US Patents: | 39 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 8,563,563 | Start Trial | Start Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 10,004,746 | Start Trial | Start Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 10,016,435 | Start Trial | Start Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | 10,653,696 | Start Trial | Start Trial | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 10,106,548 | Start Trial | Y | Y | Start Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for PHARMACYCLICS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
International Patents for Pharmacyclics Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 601278 | Start Trial |
Ecuador | SP14033163 | Start Trial |
Mexico | 347525 | Start Trial |
Philippines | 12014502681 | Start Trial |
Spain | 2616789 | Start Trial |
Eurasian Patent Organization | 201690745 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2526934 | 93321 | Luxembourg | Start Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 - IMBRUVICA - IBRUTINIB |
2526934 | 300844 | Netherlands | Start Trial | PRODUCT NAME: IBRUTINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 - C(2016)3293 20160530 |
2529621 | 122017000015 | Germany | Start Trial | PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703 |
2526934 | 273 5026-2016 | Slovakia | Start Trial | PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530 |
2201840 | 601 | Finland | Start Trial | |
2201840 | 233 5006-2015 | Slovakia | Start Trial | PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.